Atenolol drug interactions: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
mNo edit summary
Line 9: Line 9:
Calcium channel blockers may also have an additive effect when given with TENORMIN (See WARNINGS).
Calcium channel blockers may also have an additive effect when given with TENORMIN (See WARNINGS).


[[Disopyramide]] is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. [[Disopyramide]] has been associated with severe [[bradycardia]], [[asystole ]]and heart failure when administered with beta blockers.
[[Disopyramide]] is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects.
 
[[Disopyramide]] has been associated with severe [[bradycardia]], [[asystole ]]and heart failure when administered with beta blockers.


Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers.
Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers.
Line 21: Line 23:
While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.
While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.


Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of [[bradycardia]].
Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of [[bradycardia]].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TENORMIN (ATENOLOL) TABLET [ASTRAZENECA PHARMACEUTICALS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcfc9676-4edc-460e-6199-8161b824908f | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>
 
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TENORMIN (ATENOLOL) TABLET [ASTRAZENECA PHARMACEUTICALS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcfc9676-4edc-460e-6199-8161b824908f | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>


==References==
==References==
Line 30: Line 30:


[[Category:Beta blockers]]
[[Category:Beta blockers]]
[[Category:Cardiovascular Drugs]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]
[[Category:Drugs]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 02:37, 10 February 2014

Atenolol
TENORMIN ® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Atenolol
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Drug Interactions

Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with TENORMIN plus a Catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.

Calcium channel blockers may also have an additive effect when given with TENORMIN (See WARNINGS).

Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects.

Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers.

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers.

Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.

Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.

Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.

While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.[1]

References

  1. "TENORMIN (ATENOLOL) TABLET [ASTRAZENECA PHARMACEUTICALS LP]". Retrieved 5 February 2014.


Template:WikiDoc Sources